Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes

Journal of Pharmacological and Toxicological Methods

Volumn 48, Issue 2, 2002, Pages 65-80

  Witchel, Harry J ^a   Milnes, James T ^a   Mitcheson, John S ^b   Hancox, Jules C ^a  

^a SCHOOL OF MEDICAL SCIENCES   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Electrophysiological pharmacology; Gigaseal; HERG pharmacology; Leak current; Methods; Potassium channel; Trypsinisation; Xenopus oocytes

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CARRIER PROTEIN; ERYTHROMYCIN; GREEN FLUORESCENT PROTEIN; HUMAN ETHER A GO GO RELATED PROTEIN; INWARDLY RECTIFYING POTASSIUM CHANNEL; MINK RELATED PEPTIDE 1; PIPERANOMETOZINE; PLASMID DNA; POTASSIUM CHANNEL HERG; PROTEIN; RNA; SOTALOL; SULFAMETHOXAZOLE; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPSIN; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL CELL CULTURE; BETA CHAIN; CELL ISOLATION; CELL LEVEL; CELL MEMBRANE; CHLORIDE CURRENT; CHO CELL; DNA PURIFICATION; DNA TRANSFECTION; DRUG SCREENING; ELECTROPHYSIOLOGY; EXTRACELLULAR SPACE; FREEZE DRYING; GENE EXPRESSION SYSTEM; HEART MUSCLE CONDUCTION DISTURBANCE; HETEROLOGOUS EXPRESSION; HUMAN; INTRACELLULAR SPACE; LONG QT SYNDROME; MAMMAL CELL; NONHUMAN; OOCYST; PATCH CLAMP; POTASSIUM CURRENT; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QT INTERVAL; QT PROLONGATION; REVIEW; RNA PURIFICATION; RNA TRANSCRIPTION; SINGLE NUCLEOTIDE POLYMORPHISM; TEMPERATURE DEPENDENCE; TOXICITY TESTING; XENOPUS;

MAMMALIA;

EID: 0142107369     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8719(03)00041-8     Document Type: Article

References (71)

1. Abbott G.W., Goldstein S.A. Disease-associated mutations in KCNE potassium channel subunits (MiRPs) reveal promiscuous disruption of multiple currents and conservation of mechanism. FASEB Journal. 16:2002;390-400.
2. Kr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 97:1999;175-187.
3. Arcangeli A., Rosati B., Cherubini A., Crociani O., Fontana L., Passani B., Wanke E., Olivotto M. Long-term exposure to retinoic acid induces the expression of IRK1 channels in HERG channel-endowed neuroblastoma cells. Biochemical and Biophysical Research Communications. 244:1998;706-711.
4. Arcangeli A., Rosati B., Cherubini A., Crociani O., Fontana L., Ziller C., Wanke E., Olivotto M. HERG- and IRK-like inward rectifier currents are sequentially expressed during neuronal development of neural crest cells and their derivatives. European Journal of Neuroscience. 9:1997;2596-2604.
5. Arcangeli A., Rosati B., Crociani O., Cherubini A., Fontana L., Passani B., Wanke E., Olivotto M. Modulation of HERG current and herg gene expression during retinoic acid treatment of human neuroblastoma cells: Potentiating effects of BDNF. Journal of Neurobiology. 40:1999;214-225.
6. Ks cardiac potassium channel. Nature. 384:1996;78-80.
7. Blumenthal E.M., Kaczmarek L.K. The minK potassium channel exists in functional and nonfunctional forms when expressed in the plasma membrane of Xenopus oocytes. Journal of Neuroscience. 14:1994;3097-3105.
8. Busch A.E., Eigenberger B., Jurkiewicz N.K., Salata J.J., Pica A., Suessbrich H., Lang F. Blockade of HERG channels by the class III antiarrhythmic azimilide: Mode of action. British Journal of Pharmacology. 123:1998;23-30.
9. Cahalan M., Neher E. Patch clamp techniques: An overview. Methods in Enzymology. 207:1992;3-14.
10. + channels involved in long QT syndromes, are targets for calcium channel blockers. Molecular Pharmacology. 54:1998;695-703.
11. Committee for Proprietary Medicinal Products (1997). Points to consider: The assessment for the potential for QT prolongation by non-cardiovascular medicinal products. Report # CPMP/986/96. London: European Agency for the Evaluation of Medicinal Products.
12. Committee on Safety of Medicines QT interval prolongation with antipsychotics. Current Problems in Pharmacovigilance. 27:2001;4.
13. Crumb W., Cavero I. QT interval prolongation by non-cardiovascular drugs: Issues and solutions for novel drug development. Pharmaceutical Science and Technology Today. 2:1999;270-280.
14. + channel by dual pathways. Current Biology. 10:2000;671-674.
15. Daleau P., Lessard E., Groleau M.F., Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation. 91:1995;3010-3016.
16. + channel in rat F-11 DRG cell line: Pharmacological identification and biophysical characterization. Journal of Physiology (London). 496:1996;13-23.
17. 3H]Dofetilide binding to HERG transfected membranes: A potential high throughput preclinical screen. European Journal of Pharmacology. 430:2001;147-148.
18. Food and Drug Administration [FDA] USA (2002). Safety pharmacology studies for assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals: Draft ICH consensus guidelines. Available: http://www.fda.gov/cder/guidance/4970dft.PDF .
19. + channels isolated from Centruroides noxius scorpion venom. FASEB Journal. 13:1999;953-962.
20. Hancox J.C., Levi A.J., Witchel H.J. Time course and voltage dependence of expressed HERG current compared with native 'rapid' delayed rectifier K current during the cardiac ventricular action potential. Pflügers Archiv. 436:1998;843-853.
21. + channel expressed from a synthetic gene. Biochemistry. 30:1991;3341-3346.
22. Haverkamp W., Breithardt G., Camm A.J., Janse M.J., Rosen M.R., Antzelevitch C., Escande D., Franz M., Malik M., Moss A., Shah R. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovascular Research. 47:2000;219-233.
23. + channel. Nature. 423:2003;33-41.
24. + current by dofetilide. Circulation Research. 72:1993;75-83.
25. Jurman M.E., Boland L.M., Liu Y., Yellen G. Visual identification of individual transfected cells for electrophysiology using antibody-coated beads. BioTechniques. 17:1994;876-881.
26. + channels by vesnarinone. Molecular Pharmacology. 60:2001;244-253.
27. Lesage F., Attali B., Lakey J., Honore E., Romey G., Faurobert E., Lazdunski M., Barhanin J. Are Xenopus oocytes unique in displaying functional IsK channel heterologous expression? Receptors and Channels. 1:1993;143-152.
28. Levi A.J., Hancox J.C., Howarth F.C., Croker J., Vinnicombe J. A method for making rapid changes of superfusate whilst maintaining temperature at 37 degrees C. Pflügers Archiv. 432:1996;930-937.
29. Lewis J.D., Izaurralde E. The role of the cap structure in RNA processing and nuclear export. European Journal of Biochemistry. 247:1997;461-469.
30. Mazhari R., Greenstein J.L., Winslow R.L., Marban E., Nuss H.B. Molecular interactions between two long-QT syndrome gene products, HERG and KCNE2, rationalized by in vitro and in silico analysis. Circulation Research. 89:2001;33-38.
31. Kr. Nature. 388:1997;289-292.
32. Mergenthaler J., Haverkamp W., Huttenhofer A., Skryabin B.V., Musshoff U., Borggrefe M., Speckmann E.J., Breithardt G., Madeja M. Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel. Naunyn-Schmiedeberg's Archives of Pharmacology. 363:2001;472-480.
33. Milnes J.T., Crociani O., Arcangeli A., Hancox J.C., Witchel H.J. Blockade of HERG potassium currents by fluvoxamine: Incomplete attenuation by S6 mutations at F656 or Y652. British Journal of Pharmacology. 139:2003;887-898.
34. Mitcheson J.S., Chen J., Lin M., Culberson C., Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proceedings of the National Academy of Sciences, USA. 97:2000;12329-12333.
35. Mitcheson J.S., Chen J., Sanguinetti M.C. Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. Journal of General Physiology. 115:2000;229-240.
36. Netzer R., Ebneth A., Bischoff U., Pongs O. Screening lead compounds for QT interval prolongation. Drug Discovery Today. 6:2001;78-84.
37. Numaguchi H., Mullins F.M., Johnson J.P. Jr., Johns D.C., Po S.S., Yang I.C., Tomaselli G.F., Balser J.R. Probing the interaction between inactivation gating and Dd-sotalol block of HERG. Circulation Research. 87:2000;1012-1018.
38. Paul A., Witchel H.J., Hancox J.C. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide. Biochemical and Biophysical Research Communications. 280:2001;1243-1250.
39. Petrecca K., Atanasiu R., Akhavan A., Shrier A. N-linked glycosylation sites determine HERG channel surface membrane expression. Journal of Physiology. 515:1999;41-48.
40. Po S.S., Wang D.W., Yang I.C.H., Johnson J.P., Nie L., Bennett P.B. Modulation of HERG potassium channels by extracellular magnesium and quinidine. Journal of Cardiovascular Pharmacology. 33:1999;181-185.
41. Pollard J.W. Basic cell culture. Methods in Molecular Biology. 75:1997;1-11.
42. + channel, protein. Circulation. 104(Suppl. S):2001;122.
43. Rampe D., Murawsky M.K., Grau J., Lewis E.W. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. Journal of Pharmacology and Experimental Therapeutics. 286:1998;788-793.
44. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K., Strang I., Sullivan A.T., Wallis R., Camm A.J., Hammond T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research. 58:2003;32-45.
45. Robertson G.A. LQT2: Amplitude reduction and loss of selectivity in the tail that wags the HERG channel. Circulation Research. 86:2000;492-493.
46. Roy M.L., Dumaine R., Brown A.M. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation. 94:1996;817-823.
47. +-channel dysfunction in an inherited cardiac arrhythmia. Proceedings of the National Academy of Sciences, USA. 93:1996;2208-2212.
48. Ks potassium channel. Nature. 384:1996;80-83.
49. Kr potassium channel. Cell. 81:1995;299-307.
50. Schenborn E.T. Transfection technologies. Methods in Molecular Biology. 130:2000;91-102.
51. Schönherr R., Heinemann S.H. Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel. Journal of Physiology (London). 493:1996;635-642.
52. Sesti F., Abbott G.W., Wei J., Murray K.T., Saksena S., Schwartz P.J., Priori S.G., Roden D.M., George A.L.J., Goldstein S.A. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proceedings of the National Academy of Sciences, USA. 97:2000;10613-10618.
53. Shibasaki T. Conductance and kinetics of delayed rectifier potassium channels in nodal cells of the rabbit heart. Journal of Physiology (London). 387:1987;227-250.
54. Shimoni Y., Clark R.B., Giles W.R. Role of an inwardly rectifying potassium current in rabbit ventricular action potential. Journal of Physiology (London). 448:1992;709-727.
55. Smith P.L., Baukrowitz T., Yellen G. The inward rectification mechanism of the HERG cardiac potassium channel. Nature. 379:1996;833-836.
56. Smith P.L., Yellen G. Fast and slow voltage sensor movements in HERG potassium channels. Journal of General Physiology. 119:2002;275-293.
57. Snyders D.J., Chaudhary A. High affinity open channel block by dofetilide of HERG expressed in a human cell line. Molecular Pharmacology. 49:1996;949-955.
58. Splawski I., Shen J., Timothy K.W., Lehmann M.H., Priori S., Robinson J.L., Moss A.J., Schwartz P.J., Towbin J.A., Vincent G.M., Keating M.T. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation. 102:2000;1178-1185.
59. Teschemacher A.G., Seward E.P., Hancox J.C., Witchel H.J. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. British Journal of Pharmacology. 128:1999;479-485.
60. Trudeau M.C., Warmke J.W., Ganetzky B., Robertson G.A. HERG, a human inward rectifier in the voltage gated potassium channel family. Science. 269:1995;92-95.
61. Kr: The hERG channel. Journal of Molecular and Cellular Cardiology. 33:2001;835-849.
62. Wagner C.A., Friedrich B., Setiawan I., Lang F., Broer S. The use of Xenopus laevis oocytes for the functional characterization of heterologously expressed membrane proteins. Cellular Physiology and Biochemistry. 10:2000;1-12.
63. Weber M., Moller K., Welzeck M., Schorr J. Effects of lipopolysaccharide on transfection efficiency in eukaryotic cells. BioTechniques. 19:1995;930-940.
64. Weerapura M., Nattel S., Chartier D., Caballero R., Hebert T.E. A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link? Journal of Physiology. 540:2002;15-27.
65. Witchel H.J., Hancox J.C. Familial and acquired Long QT Syndrome and the cardiac rapid delayed rectifier potassium current. Clinical and Experimental Pharmacology and Physiology. 27:2000;753-766.
66. + current in cardiac cells. Circulation Research. 80:1997;782-789.
67. Yu H., Wu J., Potapova I., Wymore R.T., Holmes B., Zuckerman J., Pan Z., Wang H., Shi W., Robinson R.B., El Maghrabi M.R., Benjamin W., Dixon J., McKinnon D., Cohen I.S., Wymore R. MinK-related peptide 1: A beta subunit for the HCN ion channel subunit family enhances expression and speeds activation. Circulation Research. 88:2001;E84-E87.
68. Zhang M., Jiang M., Tseng G.N. minK-related peptide 1 associates with Kv4.2 and modulates its gating function: Potential role as beta subunit of cardiac transient outward channel? Circulation Research. 88:2001;1012-1019.
69. Zhou Z., Gong Q., Ye B., Makielski J.C., Robertson G.A., January C.T. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophysical Journal. 74:1998;230-241.
70. + channels expressed in Xenopus oocytes. American Journal of Physiology. 272:1997;H1309-H1314.
71. + channels expressed in Xenopus oocytes reduces rectification by shifting the voltage dependence of inactivation. Journal of Physiology (London). 509:1998;129-137.